Joel C Sunshine

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2388526/publications.pdf

Version: 2024-02-01

46 papers	5,020 citations	236925 25 h-index	276875 41 g-index
49 all docs	49 docs citations	49 times ranked	8451 citing authors

#	Article	IF	Citations
1	Actinic Keratosis Color and Its Associations: A Retrospective Photographic, Dermoscopic, and Histologic Evaluation. Dermatologic Surgery, 2022, 48, 57-60.	0.8	3
2	Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge. Cureus, 2022, 14, e21478.	0.5	1
3	Immune cell subsets in interface cutaneous immuneâ€related adverse events associated with <scp>antiâ€PD</scp>â€1 therapy resemble acute graft versus host disease more than lichen planus. Journal of Cutaneous Pathology, 2022, 49, 701-708.	1.3	4
4	Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms. Modern Pathology, 2021, 34, 348-357.	5.5	22
5	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
6	High-throughput evaluation of polymeric nanoparticles for tissue-targeted gene expression using barcoded plasmid DNA. Journal of Controlled Release, 2021, 337, 105-116.	9.9	18
7	A Series of RET Fusion Spitz Neoplasms With Plaque-Like Silhouette and Dyscohesive Nesting of Epithelioid Melanocytes. American Journal of Dermatopathology, 2021, 43, 243-251.	0.6	8
8	Anatomical structures, cell types and biomarkers of the Human Reference Atlas. Nature Cell Biology, 2021, 23, 1117-1128.	10.3	68
9	BRAF fusion Spitz neoplasms; clinical morphological, and genomic findings in six cases. Journal of Cutaneous Pathology, 2020, 47, 1132-1142.	1.3	17
10	Postherpes zoster programmed death-1 inhibitorâ”associated zosteriform granulomatous reactions. JAAD Case Reports, 2020, 6, 1201-1204.	0.8	3
11	Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. Journal of Immunotherapy, 2020, 43, 149-152.	2.4	5
12	Melanocytic Neoplasms With MAP2K1 in Frame Deletions and Spitz Morphology. American Journal of Dermatopathology, 2020, 42, 923-931.	0.6	19
13	Which Nanobasics Should Be Taught in Medical Schools?. AMA Journal of Ethics, 2019, 21, E337-346.	0.7	3
14	Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation. Acta Biomaterialia, 2018, 72, 228-238.	8.3	20
15	Professional medical associations and the opportunity to promote breakthrough biomedical innovation. Drug Discovery Today, 2018, 23, 1453-1456.	6.4	1
16	Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 237-246.	3.3	172
17	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
18	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	7.0	120

#	Article	IF	Citations
19	Lymphocyte Activation Gene 3 (LAG-3). , 2017, , 375-383.		1
20	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	27.0	1,048
21	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	7.1	145
22	Immunoengineering: Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells for Antigen Specific Tâ€Cell Activation (Small 13/2015). Small, 2015, 11, 1612-1612.	10.0	2
23	Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells for Antigen Specific Tâ€Cell Activation. Small, 2015, 11, 1519-1525.	10.0	148
24	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	3.5	483
25	Biomimetic particles as therapeutics. Trends in Biotechnology, 2015, 33, 514-524.	9.3	93
26	Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials, 2014, 35, 269-277.	11.4	206
27	Differential Polymer Structure Tunes Mechanism of Cellular Uptake and Transfection Routes of Poly(Î²-amino ester) Polyplexes in Human Breast Cancer Cells. Bioconjugate Chemistry, 2014, 25, 43-51.	3.6	72
28	Lymphocyte Activation Gene 3 (LAG-3). , 2014, , 1-9.		0
29	Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine, 2013, 8, 1173-1189.	3.3	67
30	The Effect and Role of Carbon Atoms in Poly(Î²-amino ester)s for DNA Binding and Gene Delivery. Journal of the American Chemical Society, 2013, 135, 6951-6957.	13.7	72
31	Gene delivery nanoparticles specific for human microvasculature and macrovasculature. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1200-1207.	3.3	38
32	Uptake and Transfection with Polymeric Nanoparticles Are Dependent on Polymer End-Group Structure, but Largely Independent of Nanoparticle Physical and Chemical Properties. Molecular Pharmaceutics, 2012, 9, 3375-3383.	4.6	133
33	Poly(Î²-Amino Ester)-Nanoparticle Mediated Transfection of Retinal Pigment Epithelial Cells In Vitro and In Vivo. PLoS ONE, 2012, 7, e37543.	2.5	82
34	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery, 2011, 8, 485-504.	5.0	53
35	Effects of Base Polymer Hydrophobicity and End-Group Modification on Polymeric Gene Delivery. Biomacromolecules, 2011, 12, 3592-3600.	5.4	102
36	Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Therapeutic Delivery, 2011, 2, 493-521.	2.2	49

#	Article	IF	Citations
37	Non-viral gene delivery nanoparticles based on Poly(Î²-amino esters) for treatment of glioblastoma. Biomaterials, 2011, 32, 5402-5410.	11.4	133
38	The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials, 2010, 31, 8088-8096.	11.4	83
39	Degradable polymers for gene delivery. , 2009, 2009, 2412-5.		3
40	Smallâ€Molecule Endâ€Groups of Linear Polymer Determine Cellâ€type Geneâ€Delivery Efficacy. Advanced Materials, 2009, 21, 4947-4951.	21.0	105
41	Gold, Poly(Î²-amino ester) Nanoparticles for Small Interfering RNA Delivery. Nano Letters, 2009, 9, 2402-2406.	9.1	258
42	Completing the Circuit:Â Direct-Observe13C,15N Double-Quantum Spectroscopy Permits Sequential Resonance Assignments near a Paramagnetic Center in Acireductone Dioxygenase. Journal of the American Chemical Society, 2008, 130, 2156-2157.	13.7	14
43	Molecular Characteristic of Variant and Classic Hairy Cell Leukemia.. Blood, 2008, 112, 1063-1063.	1.4	0
44	Immunoglobulin light chain repertoire in hairy cell leukemia. Leukemia Research, 2007, 31, 1231-1236.	0.8	7
45	Somatic hypermutation and VH gene usage in hairy cell leukaemia. British Journal of Haematology, 2006, 133, 504-512.	2.5	35
46	Using Intake Biomarkers to Evaluate the Extent of Dietary Misreporting in a Large Sample of Adults: The OPEN Study. American Journal of Epidemiology, 2003, 158, 1-13.	3.4	856